Top Page
GlaxoSmithKline
(LSE:GSK)
GlaxoSmithKline (GSK) vs. iShares MSCI United Kingdom ETF (EWC)
GlaxoSmithKline Business Overview & Revenue Model
GlaxoSmithKline Earnings Call Summary
GlaxoSmithKline Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.17B | 31.38B | 30.33B | 29.32B | 24.70B | 34.10B |
| Gross Profit | 23.28B | 21.90B | 21.25B | 19.46B | 16.34B | 23.12B |
| EBITDA | 11.27B | 6.67B | 9.14B | 8.63B | 6.45B | 10.16B |
| Net Income | 5.49B | 2.58B | 4.93B | 14.96B | 4.38B | 5.75B |
Balance Sheet | ||||||
| Total Assets | 61.34B | 59.46B | 59.01B | 60.15B | 79.10B | 80.43B |
| Cash, Cash Equivalents and Short-Term Investments | 3.31B | 3.89B | 5.69B | 7.88B | 4.33B | 6.37B |
| Total Debt | 17.75B | 17.15B | 18.02B | 20.99B | 24.17B | 27.15B |
| Total Liabilities | 45.59B | 46.38B | 46.21B | 50.05B | 57.76B | 59.62B |
| Stockholders Equity | 16.15B | 13.67B | 13.35B | 10.60B | 15.05B | 14.59B |
Cash Flow | ||||||
| Free Cash Flow | 4.70B | 3.57B | 4.42B | 5.14B | 5.02B | 6.20B |
| Operating Cash Flow | 7.79B | 6.55B | 6.77B | 7.40B | 7.95B | 8.44B |
| Investing Cash Flow | -4.42B | -1.23B | -1.59B | -8.77B | -1.78B | 2.16B |
| Financing Cash Flow | -3.67B | -4.73B | -5.64B | 823.00M | -7.59B | -10.13B |
GlaxoSmithKline Technical Analysis
GlaxoSmithKline Risk Analysis
GlaxoSmithKline Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | £194.22B | 30.25 | 22.34% | 1.54% | 10.20% | 40.57% | |
77 Outperform | £71.92B | 13.23 | 36.44% | 3.31% | 2.73% | 119.38% | |
75 Outperform | £3.89B | 13.61 | 15.66% | 3.99% | 3.73% | 27.13% | |
70 Outperform | £12.02B | 32.64 | 9.30% | 2.27% | 2.51% | 56.56% | |
68 Neutral | £4.80B | 29.62 | 12.73% | 2.20% | 4.18% | 37.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
GlaxoSmithKline Corporate Events
GSK has announced the purchase of 233,000 of its own ordinary shares as part of its ongoing buyback program, facilitated through BNP Paribas SA. This transaction, which involved shares being bought at prices ranging from 1,819.00p to 1,852.50p, contributes to GSK’s strategic financial management by increasing the number of shares held in treasury to 237,462,577. This move is part of a broader effort to manage the company’s capital structure and potentially enhance shareholder value.
GSK announced the purchase of 233,000 ordinary shares as part of its ongoing share buyback program, executed through BNP Paribas SA. This transaction is part of a broader strategy to manage its capital structure, with the company now holding 237,462,577 shares in treasury. The buyback is expected to enhance shareholder value and reflects GSK’s confidence in its financial health and future prospects.
GSK plc has announced the purchase of 218,000 of its own ordinary shares as part of its ongoing share buyback program. These shares, acquired at prices ranging from 1,830.00p to 1,848.00p, will be held as treasury shares. This transaction is part of a non-discretionary agreement with BNP Paribas SA, and since September 2025, GSK has repurchased a total of 11,764,733 ordinary shares. This move is significant as it affects the company’s capital structure and could influence shareholder value by reducing the number of shares available in the market, potentially increasing earnings per share.
GSK has announced the purchase of 200,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on December 2, 2025, is part of a larger strategy to manage its capital structure, with the company now holding over 237 million shares in treasury. The buyback program is expected to enhance shareholder value and reflects GSK’s confidence in its financial stability and future growth prospects.
GSK plc has announced the repurchase of 203,000 of its ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. The shares, purchased at a volume-weighted average price of 1,800.44 pence, will be held as treasury shares. This transaction is part of a non-discretionary agreement with the broker, contributing to a total of 11,346,733 shares repurchased since September 2025. The move is aimed at optimizing the company’s capital structure and providing value to shareholders, with the current treasury shares accounting for 5.81% of the voting rights.
GSK plc announced the grant of options over Ordinary Shares as part of its Share Save Plan 2022. This transaction, involving key executives including James Ford, David Redfern, and Victoria Whyte, took place on November 28, 2025, at the London Stock Exchange, with each transaction priced at £14.19 for 643 shares. This move is indicative of GSK’s ongoing efforts to incentivize its leadership and align their interests with company performance.
GSK has announced the purchase of 250,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas. This transaction, conducted on November 28, 2025, is part of a larger strategy to manage the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds 236,608,577 shares in treasury, with a total of 4,078,825,107 shares in issue. The buyback program is a strategic move to optimize the company’s financial position and potentially increase the value of its remaining shares.
GSK has announced the repurchase of 245,000 of its ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This move is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this transaction, GSK holds a total of 236,358,577 shares in treasury, with the total number of voting rights in the company standing at 4,079,073,350. The buyback program reflects GSK’s commitment to returning value to shareholders and maintaining a flexible balance sheet.
GSK has announced the repurchase of 170,733 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction is part of a broader strategy to manage the company’s capital structure and enhance shareholder value, with the shares being held as treasury shares. Following this purchase, GSK holds 236,113,577 shares in treasury, representing 5.79% of the voting rights, which could influence shareholder decisions and market perceptions.
GSK has announced the purchase of 170,000 of its own ordinary shares as part of its ongoing buyback program, with shares acquired through BNP Paribas SA. The shares will be held as treasury shares, and this transaction contributes to the company’s strategy to manage its capital structure and return value to shareholders. The buyback program, initiated on 30 September 2025, has seen GSK purchase a total of 10,478,000 shares. This move is expected to impact the company’s voting rights and shareholding structure, with 5.78% of voting rights now attributable to treasury shares.
GSK plc announced the repurchase of 170,000 of its ordinary shares as part of its ongoing buyback program, with shares purchased at prices ranging from 1,775.50p to 1,793.50p. This transaction, executed through BNP Paribas SA, increases the total number of shares held in treasury to 235,772,844, representing 5.78% of the company’s voting rights. The buyback program aims to optimize the company’s capital structure and return value to shareholders, potentially impacting market perceptions and shareholder interests.
GSK plc announced the purchase of 180,000 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired at a volume-weighted average price of 1,766.33 pence, will be held as treasury shares. This transaction, facilitated through BNP Paribas SA, contributes to the total of 10,138,000 shares repurchased since the program’s announcement on 30 September 2025. Following this purchase, GSK holds 235,602,844 shares in treasury, with a total of 4,079,829,083 shares in issue, excluding treasury shares. This buyback effort is part of GSK’s strategy to manage its capital structure and return value to shareholders.
GSK has announced the purchase of 360,000 of its ordinary shares as part of its ongoing buyback program. This transaction, executed through BNP Paribas, reflects GSK’s strategy to manage its capital structure and enhance shareholder value. Following this purchase, GSK holds 235,422,844 shares in treasury, with a total of 4,080,008,266 shares in issue, impacting the voting rights and shareholding structure.
TESARO, a subsidiary of GSK, has initiated litigation against AnaptysBio, Inc. in the Delaware Chancery Court, alleging a breach of the license agreement concerning the oncology treatment Jemperli (dostarlimab). This legal action seeks to terminate the current license agreement, secure a perpetual license for dostarlimab, and reduce royalties and milestone payments to AnaptysBio by 50%. Jemperli, approved in over 35 countries for endometrial cancer, has seen significant growth due to label expansions, with ongoing clinical trials exploring its use in other cancers. This litigation could impact GSK’s operations and market positioning in oncology treatments.
GlaxoSmithKline (GSK) has announced the purchase of 243,000 of its own ordinary shares as part of its ongoing share buyback program. The shares, acquired through BNP Paribas SA, will be held as treasury shares, increasing the company’s total treasury shares to 235,062,844. This move is part of a non-discretionary agreement with the broker and reflects GSK’s strategy to manage its capital structure effectively. The transaction impacts the voting rights percentage of the company, which shareholders can use to assess their interests under regulatory guidelines.
GSK plc has announced the purchase of 185,000 of its ordinary shares as part of its ongoing share buyback program. The shares, acquired through BNP Paribas SA, will be held as treasury shares, increasing the total number held to 234,819,844. This transaction is part of a non-discretionary agreement aimed at enhancing shareholder value and optimizing the company’s capital structure.
GSK plc announced the acquisition of American Depositary Shares (ADSs) by Dr. Hal Barron, a Non-Executive Director, and James Ford, SVP and Group General Counsel, through the reinvestment of dividends in their respective savings plans. These transactions, conducted on the New York Stock Exchange, reflect the company’s ongoing commitment to aligning executive interests with shareholder value.
GlaxoSmithKline (GSK) announced the repurchase of 170,000 ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, conducted on November 17, 2025, involved shares purchased at prices ranging from 1,781.00p to 1,800.50p, with an average price of 1,789.39p. The repurchased shares will be held as treasury shares, contributing to a total of 256,634,844 shares in treasury. This move is part of GSK’s strategy to manage its capital structure and return value to shareholders, reflecting confidence in its financial health and future prospects.
GlaxoSmithKline (GSK) has announced the purchase of 170,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, conducted through BNP Paribas, is part of a larger strategy to manage the company’s capital structure and return value to shareholders. Following this purchase, GSK holds a total of 256,464,844 shares in treasury, with 4,058,966,266 shares remaining in issue. The buyback program reflects GSK’s confidence in its financial health and commitment to enhancing shareholder value.
GSK has announced the repurchase of 167,000 of its own shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction is part of a larger strategy initiated on September 30, 2025, which has seen the company buy back a total of 8,830,000 shares. The repurchased shares will be held as treasury shares, impacting the company’s voting rights and share distribution, with 6.31% of voting rights now attributable to treasury shares. This move reflects GSK’s efforts to manage its capital structure and return value to shareholders.
GSK plc announced the acquisition of ordinary shares by several of its senior executives, including the CEO and CFO, under the company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, highlights the company’s commitment to aligning the interests of its leadership with those of its shareholders, potentially strengthening stakeholder confidence in GSK’s strategic direction.
GSK has announced the purchase of 167,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on November 12, 2025, is part of a larger initiative that has seen the company repurchase 8,663,000 shares since September 30, 2025. The repurchased shares will be held as treasury shares, and the total number of voting rights in the company remains at 4,059,300,530. This move is expected to impact the company’s financial structure and shareholder value, reflecting GSK’s strategic focus on optimizing its capital allocation.
GlaxoSmithKline (GSK) plc has announced the purchase of 167,000 of its own ordinary shares, as part of its ongoing share buyback program. The shares, purchased through BNP Paribas SA, will be held as treasury shares. This transaction is part of a larger buyback initiative that has seen the company acquire 8,496,000 shares since September 30, 2025. The buyback program is designed to optimize the company’s capital structure and potentially enhance shareholder value by reducing the number of shares outstanding.
GlaxoSmithKline (GSK) has announced a recent purchase of 170,000 of its own ordinary shares as part of its existing buyback program. This transaction, executed through BNP Paribas SA, reflects GSK’s strategy to manage its capital structure effectively by holding these shares in treasury. Following this purchase, GSK now holds 255,793,844 ordinary shares in treasury, with a total of 4,059,634,530 shares in issue. This move is part of a broader buyback initiative that has seen the company acquire over 8 million shares since late September 2025, potentially impacting shareholder value and market perception.
GSK plc has announced provisional dividend dates for the year 2026, outlining key dates for ordinary shares and American Depositary Shares. These dates are subject to change and provide stakeholders with a timeline for dividend-related activities, reflecting GSK’s commitment to maintaining transparency and shareholder engagement.
GSK announced the purchase of 170,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, part of a non-discretionary agreement, brings the total number of shares held in treasury to 255,623,844, with 4,059,804,530 shares remaining in issue. The buyback program is designed to optimize the company’s capital structure and potentially enhance shareholder value.
GSK has announced the purchase of 170,000 of its own ordinary shares as part of an ongoing buyback program, facilitated through BNP Paribas. This transaction is part of a larger strategy initiated on September 30, 2025, which has seen the company acquire a total of 7,989,000 shares. These shares will be held in treasury, impacting the total number of voting rights and potentially influencing shareholder interest calculations under regulatory guidelines.
GSK plc has announced the purchase of 170,000 of its own ordinary shares as part of its ongoing buyback programme, facilitated through BNP Paribas SA. This move increases the company’s treasury shares to 255,283,844, while the total number of voting rights remains at 4,060,139,755. The buyback is part of a strategic effort to manage the company’s capital structure and potentially enhance shareholder value.
GSK has announced the purchase of 175,000 of its own ordinary shares as part of its ongoing share buyback program. The shares, purchased at prices ranging from 1,747.00p to 1,790.00p, will be held as treasury shares. This move is part of a non-discretionary agreement with BNP Paribas SA, and since September 2025, GSK has acquired a total of 7,649,000 shares. The buyback program aims to optimize the capital structure and return value to shareholders, impacting the company’s financial strategy and shareholder equity.
GlaxoSmithKline (GSK) has announced a recent transaction involving the repurchase of 170,500 of its ordinary shares, as part of its ongoing buyback program. This move, executed through BNP Paribas SA, reflects the company’s strategy to manage its capital structure and enhance shareholder value. The shares were acquired at prices ranging from 1,758.50p to 1,782.00p and will be held as treasury shares. Following this transaction, GSK holds a total of 254,938,844 shares in treasury, with 4,060,484,755 shares remaining in issue.
GSK plc has announced its total voting rights and capital as of October 31, 2025, in compliance with the Financial Conduct Authority’s rules. The company reported an issued share capital of over 4.3 billion shares, with a total of 4,060,655,255 voting rights available. This information is crucial for shareholders to determine their notification obligations regarding changes in their interest in the company.
GSK has announced the purchase of 175,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas. This transaction is part of a non-discretionary agreement with the broker, and since September 30, 2025, GSK has acquired a total of 7,303,500 shares. The purchased shares will be held as treasury shares, and the company now holds 254,768,344 shares in treasury, with 4,060,655,255 shares in issue. This move is likely to impact the company’s share value and voting rights, with treasury shares accounting for 6.27% of voting rights, potentially affecting shareholder calculations under regulatory guidelines.
GSK has announced the purchase of 180,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas. This transaction, part of a non-discretionary agreement, contributes to the total of 7,128,500 shares bought back since September 2025. The shares will be held as treasury shares, and the company now holds a total of 254,593,344 shares in treasury, with 4,060,827,442 shares in issue. This move is likely to impact the company’s stock value and shareholder voting rights, with treasury shares accounting for 6.27% of voting rights.
GSK plc announced that Regis Simard, President of Global Supply Chain, and Deborah Waterhouse, CEO of ViiV Healthcare and President of Global Health, have sold a significant number of ordinary shares on the London Stock Exchange. These transactions, involving 37,000 shares by Simard and 120,000 shares by Waterhouse, could have implications for investor confidence and the company’s stock market performance.
GSK plc has announced the repurchase of 180,000 ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. The shares, purchased at prices ranging from 1,669.50p to 1,761.00p, will be held in treasury, increasing the total to 254,413,344 treasury shares. This move is part of a broader strategy to manage capital and return value to shareholders, reflecting the company’s robust financial position and commitment to enhancing shareholder value.
GSK has announced the purchase of 320,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through BNP Paribas SA, reflects GSK’s strategy to manage its capital structure and return value to shareholders. The shares will be held as treasury shares, and the company now holds 254,233,344 shares in treasury, with a total of 4,061,187,442 shares in issue. This buyback is part of a broader effort to enhance shareholder value and optimize the company’s financial flexibility.
GSK has reported a strong performance for the third quarter of 2025, with sales reaching £8.5 billion, driven by significant growth in specialty medicines, vaccines, and general medicines. The company has upgraded its guidance for 2025, expecting turnover growth between 6% to 7%, core operating profit growth between 9% to 11%, and core EPS growth between 10% to 12%. This performance is attributed to robust sales in respiratory, oncology, and HIV segments, as well as strategic investments in R&D and pipeline advancements. GSK has also achieved four major new product approvals this year and is progressing with pivotal trials for future growth opportunities. The company remains committed to shareholder returns, declaring a dividend and continuing its share buyback program.
GSK has announced that its B7-H3-targeted antibody-drug conjugate, GSK’227, has received Orphan Drug Designation from the European Medicines Agency for the treatment of pulmonary neuroendocrine carcinoma, including small-cell lung cancer. This designation highlights GSK’227’s potential to address significant unmet needs in this aggressive cancer type, which has limited treatment options and poor outcomes. The designation is based on promising early clinical data and supports GSK’s strategy to accelerate the development of antibody-drug conjugates across various solid tumors, reinforcing its position in the oncology market.
GlaxoSmithKline (GSK) has announced the purchase of 166,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through BNP Paribas SA, is part of a larger effort that has seen GSK acquire over 6.4 million shares since September 2025. The purchased shares will be held as treasury shares, and the company now holds a total of 253,913,344 shares in treasury, with a total of 4,061,507,442 shares in issue. This move is likely to impact the company’s share value and could influence shareholder decisions regarding their investments.
GSK has announced the purchase of 555,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on October 24, 2025, is part of a broader strategy to manage the company’s capital structure and return value to shareholders. Following this purchase, GSK holds 253,747,344 shares in treasury, with a total of 4,061,673,442 shares in issue, excluding treasury shares. The buyback program reflects GSK’s commitment to enhancing shareholder value and maintaining a robust financial position.
GSK has announced the purchase of 366,000 of its own ordinary shares, as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on 23 October 2025, is part of a broader strategy to manage the company’s capital structure and return value to shareholders. Following this purchase, GSK holds 253,192,344 shares in treasury, with a total of 4,062,224,575 shares in issue, impacting the voting rights and shareholding calculations for stakeholders.
GSK announced that the US FDA has approved Blenrep for treating relapsed or refractory multiple myeloma in adults who have undergone at least two prior therapies. This approval is based on the DREAMM-7 trial, which showed significant improvements in survival and progression-free survival. Blenrep is the only anti-BCMA treatment available in community settings, addressing a major patient need. GSK is advancing its clinical program to explore Blenrep’s potential in earlier treatment stages, with ongoing trials and future data submissions planned to further solidify its role in the multiple myeloma treatment landscape.
GSK has announced the purchase of 248,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This move is part of a broader strategy initiated on September 30, 2025, which has seen the company repurchase over 5.3 million shares, aiming to enhance shareholder value and optimize capital structure. Following this transaction, GSK holds over 252 million shares in treasury, representing 6.22% of the company’s voting rights, a figure relevant for shareholder interest calculations under regulatory guidelines.
GSK has announced positive results from its phase III clinical trials for a next-generation low carbon version of its Ventolin (salbutamol) metered dose inhaler (MDI). This new formulation, which uses an innovative low carbon propellant, shows therapeutic equivalence and safety comparable to the current version. If approved, it could reduce greenhouse gas emissions by 92% per inhaler, significantly impacting GSK’s carbon footprint and supporting global climate targets. The company plans to proceed with regulatory submissions, with a launch expected in 2026, offering a more sustainable option for patients with respiratory diseases.
GSK and Alector announced the results of the INFRONT-3 clinical trial for latozinemab, a treatment for frontotemporal dementia due to a progranulin gene mutation. While the trial showed a significant effect on plasma progranulin concentrations, it did not demonstrate clinical benefits in slowing disease progression, leading to the discontinuation of further studies. Despite this setback, GSK remains committed to exploring the data for future research opportunities in neurodegeneration.
GSK plc has announced the purchase of 250,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, part of a non-discretionary agreement, brings the total shares held in treasury to 252,578,344, representing 6.22% of the company’s voting rights. The buyback initiative is aimed at optimizing the capital structure and providing returns to shareholders, reflecting GSK’s strategic focus on enhancing shareholder value.
GSK announced that the European Medicine Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion on the approval of Shingrix in a prefilled syringe format. This new presentation simplifies the administration process for healthcare professionals and is expected to receive marketing authorization in the EU by December 2025, potentially enhancing GSK’s market position in the shingles vaccine sector.
GSK and Spero Therapeutics announced promising results from the phase III PIVOT-PO trial for tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs). The trial demonstrated that tebipenem HBr is non-inferior to intravenous imipenem-cilastatin, offering a potential new oral option that could reduce hospital stays for cUTI patients. This development is significant given the high healthcare costs and serious risks associated with cUTIs, often caused by multidrug-resistant pathogens. If approved, tebipenem HBr would be the first oral carbapenem antibiotic in the US, enhancing GSK’s anti-infectives portfolio and addressing antimicrobial resistance challenges.
GSK has announced the purchase of 220,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through BNP Paribas SA, reflects GSK’s strategy to manage its capital structure and potentially enhance shareholder value. The shares will be held as treasury shares, increasing the total to 252,328,344, while the total number of voting rights remains at 4,063,088,575. This move may influence shareholder calculations regarding their interests in the company.
GSK has announced the purchase of 414,000 of its own ordinary shares as part of its ongoing buyback program, with shares being held as treasury stock. This transaction, executed through BNP Paribas SA, reflects GSK’s strategic financial management aimed at optimizing shareholder value. Following this purchase, GSK holds a total of 252,108,344 ordinary shares in treasury, with 4,063,308,575 shares remaining in issue, impacting the voting rights percentage and potentially influencing shareholder decisions.
GSK plc has announced the purchase of 310,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through BNP Paribas SA, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds 251,694,344 shares in treasury, with a total of 4,063,719,485 shares in issue, excluding treasury shares. The buyback program reflects GSK’s commitment to returning value to shareholders and optimizing its capital allocation.
GSK announced the acquisition of American Depositary Shares (ADSs) by key company executives, including Dr. Hal Barron, James Ford, and Shobie Ramakrishnan, following the reinvestment of dividends paid to shareholders. These transactions, conducted on the New York Stock Exchange, reflect the company’s ongoing commitment to aligning executive interests with shareholder value, potentially enhancing stakeholder confidence in GSK’s market strategies.
GSK has announced the purchase of 405,500 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, completed on October 15, 2025, reflects GSK’s strategic approach to managing its capital structure and enhancing shareholder value. Following this purchase, GSK holds 251,384,344 shares in treasury, with a total of 4,064,029,485 shares in issue, excluding treasury shares. The buyback program is significant for stakeholders as it indicates GSK’s confidence in its financial stability and commitment to returning value to shareholders.
GSK plc announced an increase in notional interest in its ordinary shares for several key executives, including the CEO and CFO, following the reinvestment of dividends paid on October 9, 2025. This transaction, conducted on the London Stock Exchange, reflects the company’s ongoing commitment to aligning executive interests with shareholder value through its Deferred Annual Bonus Plan.
GSK has announced the purchase of 270,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, part of a larger initiative since September 2025, aims to enhance shareholder value by reducing the number of shares in circulation, thereby potentially increasing the value of remaining shares. The company now holds 250,978,844 shares in treasury, with a total of 4,064,434,985 shares in issue, impacting the voting rights and shareholding calculations for stakeholders.
GSK plc announced the purchase of 340,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on October 13, 2025, reflects GSK’s strategy to manage its capital structure and enhance shareholder value, with the purchased shares being held as treasury shares. The buyback program is a significant move in maintaining the company’s market positioning and optimizing its financial operations.
GSK has announced that its Shingrix vaccine has been approved by the China National Medical Products Administration for use in adults aged 18 and over who are at increased risk of shingles due to immunodeficiency or immunosuppression. This approval marks Shingrix as the first and only vaccine available for this demographic in China, expanding its existing indication for adults aged 50 and over. The approval is significant given the high incidence of shingles in China, with approximately six million cases annually, and it underscores GSK’s commitment to protecting vulnerable populations and enhancing healthcare systems’ focus on disease prevention.
GSK plc announced the acquisition of ordinary shares by several key executives, including the CEO and other senior leaders, through the reinvestment of dividends as part of the company’s Share Reward Plan. These transactions, conducted on the London Stock Exchange, reflect the company’s ongoing commitment to aligning the interests of its leadership with those of its shareholders, potentially impacting stakeholder confidence and market perception.
GSK announced the purchase of 355,000 of its ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, conducted on October 10, 2025, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds a total of 250,368,844 shares in treasury, representing 6.16% of the voting rights, which may influence shareholder calculations under regulatory guidelines.
GSK plc announced the acquisition of ordinary shares by several of its key executives under the company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involves notable figures such as CEO Emma Walmsley and CFO Julie Brown, among others, and reflects GSK’s commitment to aligning the interests of its leadership with those of its shareholders.
GSK has announced the purchase of 295,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, conducted through BNP Paribas SA, reflects the company’s strategy to manage its capital structure and enhance shareholder value, with the purchased shares held as treasury shares.
GlaxoSmithKline (GSK) has announced the purchase of 308,000 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired through BNP Paribas SA, will be held as treasury shares. This transaction is part of a broader strategy to manage the company’s capital structure and return value to shareholders, with GSK having purchased a total of 2,254,000 shares since the end of September 2025. The buyback is expected to impact the company’s voting rights structure, with 6.14% of voting rights now attributable to treasury shares.
GlaxoSmithKline (GSK) has announced the purchase of 354,000 of its own ordinary shares as part of its ongoing buyback program. The shares, purchased at prices ranging from 1,597.50p to 1,611.50p, will be held as treasury shares. This move is part of a non-discretionary agreement with BNP Paribas SA, and since September 30, 2025, GSK has acquired a total of 1,946,000 shares. The company now holds 249,410,844 shares in treasury, with 4,065,997,695 shares in issue. This buyback strategy is likely aimed at optimizing capital structure and potentially enhancing shareholder value.
GSK has announced the purchase of 340,000 of its own ordinary shares as part of its ongoing buyback program. This move, executed through BNP Paribas SA, reflects the company’s strategy to manage its capital structure and enhance shareholder value. The shares will be held as treasury shares, and this transaction increases the total number of shares held in treasury to 249,056,844, representing 6.12% of the company’s voting rights. This buyback is part of a broader initiative that has seen the company repurchase 1,592,000 shares since September 30, 2025, potentially impacting the company’s stock liquidity and market perception.
GSK has announced the purchase of 350,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on October 3, 2025, is part of a broader strategy to optimize the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds a total of 248,716,844 shares in treasury, with the total number of voting rights in the company standing at 4,066,691,695. This move reflects GSK’s commitment to returning value to its shareholders and maintaining a strong market position.
GSK plc announced the purchase of 335,000 of its own ordinary shares as part of its ongoing buyback program, with the shares held as treasury stock. This move is part of a non-discretionary agreement with BNP Paribas SA and reflects the company’s strategy to manage its capital structure, potentially enhancing shareholder value and market confidence.
GSK plc has announced its total voting rights and capital as of September 30, 2025. The company’s issued share capital consists of over 4.3 billion ordinary shares, with a total of approximately 4.07 billion voting rights available. This information is crucial for shareholders to determine their required notifications under the Financial Conduct Authority’s rules.
GSK has announced the purchase of 305,000 ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, completed on September 30, 2025, reflects GSK’s strategic financial management to enhance shareholder value. The shares will be held as treasury shares, and following this purchase, GSK holds 247,769,844 shares in treasury, with a total of 4,067,637,496 shares in issue. This move is significant for stakeholders as it impacts the voting rights and share distribution, with treasury shares now accounting for 6.09% of the voting rights.
GSK has announced the commencement of the third tranche of its £2 billion share buyback programme, which aims to return excess capital to shareholders and enhance earnings per share. This tranche, valued at up to £0.3 billion, will be executed through a non-discretionary agreement with BNP Paribas and is expected to be completed by December 2025, reflecting GSK’s strategic focus on optimizing shareholder value.
GSK has announced the appointment of Luke Miels as CEO Designate, who will take over full responsibilities as CEO from January 1, 2026. Miels, who has been with GSK since 2017 as Chief Commercial Officer, has played a key role in expanding the company’s specialty medicines portfolio. He will succeed Dame Emma Walmsley, who has significantly transformed GSK’s operations, including the creation of Haleon, a leader in consumer health. This leadership change marks a pivotal phase for GSK as it aims for long-term growth with sales expectations exceeding £40 billion by 2031.
GSK plc announced the purchase of shares by several of its independent non-executive directors, including Wendy Becker, Elizabeth McKee Anderson, Charles Bancroft, Dr Hal Barron, Dr Anne Beal, Dr Hal Dietz, Dr Jeannie Lee, and Dr Vishal Sikka. These transactions, which took place on September 19, 2025, involved the acquisition of ordinary shares and American Depositary Shares (ADSs) on the London Stock Exchange and New York Stock Exchange, respectively. This move reflects the directors’ confidence in the company’s future prospects and may positively impact stakeholder perceptions.
GSK has announced the purchase of 15,858 of its own ordinary shares as part of its ongoing buyback program, conducted through Merrill Lynch International. This transaction, which is part of a non-discretionary agreement made in June 2025, aims to manage the company’s capital structure and potentially enhance shareholder value. Following this purchase, GSK holds 247,464,844 shares in treasury, with a total of 4,067,938,124 shares in issue, excluding treasury shares. The move reflects GSK’s strategic financial management and impacts its voting rights, which now stand at 6.08% for treasury shares.
GSK has announced the repurchase of 209,886 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which took place on September 17, 2025, is part of a larger strategy to manage the company’s capital structure and return value to shareholders. Following this purchase, GSK holds 247,448,986 shares in treasury, with a total of 4,067,953,982 shares in issue. The buyback is expected to enhance shareholder value and reflects the company’s confidence in its financial health and future prospects.
GlaxoSmithKline (GSK) has announced the repurchase of 210,377 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Merrill Lynch International, reflects GSK’s strategic efforts to manage its capital structure and enhance shareholder value. The shares will be held as treasury shares, and the company now holds a total of 247,239,100 ordinary shares in treasury. The buyback is part of a non-discretionary agreement and contributes to the company’s financial strategy, potentially impacting shareholder voting rights and market perceptions.
GSK has announced a significant investment of $30 billion in the United States over the next five years, aimed at enhancing research and development and supply chain infrastructure. This includes a $1.2 billion investment in advanced manufacturing facilities and digital technologies, which will create hundreds of skilled jobs and strengthen the company’s presence in the U.S. life sciences sector. The initiative highlights GSK’s commitment to innovation and its strategic focus on respiratory and cancer medicines, further solidifying its leadership in the biopharma industry.
GSK has announced the purchase of 253,331 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, part of a non-discretionary agreement initiated in June 2025, brings the total number of shares held in treasury to 247,028,723, representing 6.07% of the company’s voting rights. The buyback strategy is aimed at optimizing the capital structure and returning value to shareholders, potentially impacting the company’s stock market performance and investor relations.
GSK has announced the purchase of 203,447 of its own ordinary shares as part of an ongoing buyback program, with the shares to be held in treasury. This transaction, executed through Merrill Lynch International, reflects GSK’s strategy to manage its capital structure and return value to shareholders. Following this purchase, GSK holds 246,775,392 shares in treasury, representing 6.07% of the voting rights, which may impact shareholder calculations under regulatory guidelines.
GSK has announced the purchase of 205,355 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction is part of a non-discretionary agreement initiated in June 2025, and the shares will be held as treasury shares. The buyback program reflects GSK’s strategy to manage its capital structure and enhance shareholder value, with the company now holding 246,571,945 shares in treasury. The total number of voting rights in the company remains at 4,068,829,782.
GSK announced the purchase of 205,355 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, conducted on the London Stock Exchange, is part of a non-discretionary agreement established in June 2025, and it contributes to the company’s strategy to manage its capital structure effectively, impacting the voting rights and shareholding structure.
GSK announced the repurchase of 213,147 of its ordinary shares as part of its ongoing buyback program, executed through its broker Merrill Lynch International. This transaction is part of a larger strategy initiated in June 2025, which has seen the company repurchase over 28 million shares. The shares will be held as treasury shares, affecting the company’s voting rights and share capital structure. This move is likely to impact shareholder value and market perception positively, as buybacks often signal confidence in the company’s financial health.
GSK plc announced the acquisition of ordinary shares by several key executives under the company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of shares by the CEO, CFO, and other senior executives, reflecting their commitment to the company’s growth and aligning their interests with shareholders.
GSK has announced the purchase of 207,767 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which forms part of a non-discretionary agreement, increases the company’s treasury shares to 246,153,443, representing 6.05% of the voting rights. The buyback is part of GSK’s strategy to manage its capital structure and return value to shareholders.
GSK has announced the purchase of 219,116 of its own ordinary shares as part of its ongoing buyback program. This transaction, conducted through Merrill Lynch International, is part of a non-discretionary agreement and contributes to the company’s efforts to manage its capital structure, potentially impacting shareholder value and market perception.
GlaxoSmithKline (GSK) has announced the repurchase of 219,116 of its ordinary shares as part of its ongoing buyback program. The shares were bought at a volume-weighted average price of 1,460.93 pence per share and will be held as treasury shares. This move is part of a non-discretionary agreement with Merrill Lynch International and reflects GSK’s strategy to manage its capital structure effectively. The repurchase increases the total number of shares held in treasury to 245,945,676, representing 6.04% of the company’s voting rights, which could impact shareholder calculations under the Financial Conduct Authority’s rules.
GSK has announced the repurchase of 276,710 ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This move is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this transaction, GSK now holds 245,726,560 shares in treasury, with a total of 4,069,675,167 shares in issue, affecting the voting rights and potentially impacting shareholder decisions.